Lawyers are helping those diagnosed with Cutaneous T-Cell Lymphoma or T-Cell Lymphoma after taking the popular eczema and asthma drug.
A summary of Dupixent risks and current status of lawsuits:
You may be eligible for substantial compensation if you were a patient who used Dupixent and was later diagnosed with T-Cell Lymphoma. To see if you qualify, complete the case review form.
Dupixent (generic name dupilumab) is a popular injectable prescription drug used to treat conditions like:
Since it was first approved by the FDA in 2017, Dupixent has been given to more than 1 million patients in 60 countries, with hundreds of thousands in the United States.
The most common side effects reported by the drug’s manufacturers, Sanofi and Regeneron, are allergic reactions, skin irritation, eye problems, nausea, vomiting, stomach pain and joint pain.
Unfortunately, several international studies have recently found much greater risks. Specifically, people who were given Dupixent shots may face a 300% to 450% higher risk of dangerous cancers like Cutaneous T-Cell Lymphoma (CTCL) and T-Cell Lymphoma (TCL).
Patients have reported developing or worsening of these aggressive cancers that affect the immune system, and may appear on the skin as rashes, lesions, or tumors.
Due to the failure of the drug’s manufacturers to warn patients and doctors of these risks, experts fear thousands of people may have been affected with cancer.
Lawyers are currently helping those affected. If you or a loved one were diagnosed with Cutaneous T-Cell Lymphoma or T-Cell Lymphoma after being given Dupixent, you may be eligible to file a lawsuit.
Studies into the cancer risks of Dupixent show the manufacturers had reason to suspect their drug may present serious Cutaneous T-Cell Lymphoma dangers for patients as early as 2020.
In 2020 the Journal of the American Academy of Dermatology published a 2019 study from Medstar Washington Hospital and Georgetown University showing that patients experienced a worsening of CTCL symptoms while using dupilumab.
Then, in April 2024 a team of researchers from West Virginia University School of Medicine discovered patients who were given Dupixent injections had a 300% higher risk of getting CTCL than those who didn’t.
An August 2024 study from Thomas Jefferson University found that people who were given Dupixent had a 350% higher risk of developing cutaneous T-cell lymphoma compared to those who didn’t get the injections.
Finally, a joint study by researchers at Massachusetts General Hospital and Harvard University in June 2025 revealed that asthma patients who were given Dupixent shots suffered CTCL at 450% higher rates than those who received other treatments.
Shockingly, in patients who received 16 weeks of Dupixent treatment, the risk of lymphoma was over 14 times higher than with other treatments.
Despite this overwhelming research, the manufacturers of Dupixent still have not warned doctors or patients of these risks.
Latest Information on the Dupixent Litigation
No. Lawyers expect thousands of victims will eventually file lawsuits against Sanofi and Regeneron for Cutaneous T-Cell Lymphoma suffered as a result of taking Dupixent without warning. However, claims are likely to be consolidated into special multidistrict litigation courts rather than a Class Action Lawsuit.
In order to handle the volume of cases most efficiently, lawsuits that claim similar injuries from one product, like Dupixent, are often consolidated into specific courts like these.
Instead of forcing people into a single class action lawsuit for Dupixent cancer, multidistrict litigation (MDL) courts allow victims to band their individual cases together in a special court to seek damages against Sanofi and Regeneron.
This process offers more advantages to victims than class action lawsuits. In a class action, lawyers gather class participants together, who must then share whatever is awarded. However, individual participants in an MDL select their own lawyer, have more control over their case and whether it settles, and reap higher award amounts for their separate lawsuit.
DrugNews works only with lawyers that have handled tens of thousands of defective drug and medical device injury cases and are integrally involved with MDL litigation and courts.
If you or a loved one have been diagnosed with Cutaneous T-Cell Lymphoma or T-Cell Lymphoma after taking Dupixent shots, it’s important to speak with a lawyer about your potential recovery and legal options before your rights expire.
Our qualified drug injury lawyers will fully investigate your case, reviewing medical records, safety warnings, recalls and recent studies that your doctor may not normally discuss.
Most states allow you several years to file a lawsuit after you suffer an injury or discover it may be linked to a dangerous product. However, you should begin the process as early as possible to make sure your lawyer has time to get necessary records and prepare your case.
DrugNews works only with attorneys and law firms that have successfully handled tens of thousands of lawsuits involving injury or death from drugs and medical devices. And, you can speak directly with a lawyer or patient advocate today, so you’ll be able to decide if you want to proceed.
We make it easy to get help, find out if you qualify, and quickly file a claim. Our service is offered at no cost to you, and you won’t pay anything to your attorney unless you receive an award. Also, our qualified lawyers can handle most aspects of your case without you ever having to leave your home.
For more information, or to learn about your options - call, chat or email us today.
Call, email or live chat with us today to see how we can help.
